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Abstract:  
Background 
Some HIV infected individuals initiating combination antiretroviral therapy (cART) with low CD4 
counts achieve viral suppression but not CD4 cell recovery. We aimed to identify (1) risk factors for 
failure to achieve CD4 count >200 cells/µL after three years of sustained viral suppression and (2) 
the association of achieved CD4 count with subsequent mortality. 
Methods 
We included treated HIV infected adults from two large international HIV cohorts, who were 
virally suppressed (≤500 HIV-1 RNA copies/ml) for >3 years with CD4 count ≤200 cells/µL at start 
of the suppressed period. Logistic regression was used to identify risk factors for incomplete CD4 
recovery (≤200 cells/µL) and Cox regression to identify associations with mortality.  
Results 
Of 5550 eligible individuals, 835 (15%) did not reach CD4 count >200 cells/µL after three years of 
suppression. Increasing age, lower initial CD4 count, male heterosexual and injection drug use 
transmission, cART initiation after 1998 and longer time from initiation of cART to start of the 
virally suppressed period were risk factors for not achieving CD4 count >200 cells/µL. Individuals 
with CD4 ≤200 cells/µL after three years of viral suppression had substantially increased mortality 
(adjusted hazard ratio 2.60; 95% confidence interval 1.86-3.61) compared to those who achieved 
CD4 count >200 cells/µL. The increased mortality was seen across different patient groups and for 
all causes of death.  
Conclusions 
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Virally suppressed HIV positive individuals on cART who do not achieve CD4 count >200 cells/µL 
have substantially increased long-term mortality. 
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Main manuscript: 
Introduction  
The introduction of combination antiretroviral therapy (cART) has decreased morbidity and 
mortality in HIV positive individuals due to viral suppression and CD4 cell recovery (1-3). 
However, some individuals treated with cART achieve viral suppression but not CD4 cell recovery 
(4-6). Several studies have shown that individuals with successful virological response to cART and 
incomplete CD4 recovery have increased mortality (4;5;7-9). However, the only previous study 
exclusively examining the long-term mortality in individuals started late on cART with sustained 
viral load (VL) suppression and low CD4 count is limited by small sample size (8).  
By combining data from two large international collaborations of HIV cohorts, The Antiretroviral 
Therapy Cohort Collaboration (ART-CC) and The Collaboration of Observational HIV 
Epidemiological Research Europe (COHERE), we examined risk factors for failure to achieve CD4 
recovery among treated individuals who were virally suppressed for more than three years, and 
compared mortality rates after three years of viral suppression according to CD4 count reached at 
end of the virally suppressed period. 
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Methods 
Setting and participants 
The ART-CC is an international collaboration of 18 cohort studies of HIV-1 positive individuals 
from Europe and North America which was established in 2000 to examine the prognosis of HIV-1 
positive, treatment-naive individuals initiating cART (10). COHERE was established in 2005 and is 
an international collaboration of 35 cohorts from 29 European countries. The COHERE data were 
pooled within the EuroCoord network (www.EuroCoord.net). Each collaboration focuses on 
scientific questions requiring large sample sizes, which the contributing cohorts cannot answer 
individually (11). Further information about the two collaborations is available at http://www.art-
cohort-collaboration.org and http://www.COHERE.org.  
 
Study population and design 
We identified all HIV-1 positive individuals who: 1) were >16 years old at start of the suppressed 
period, 2) were on cART continuously (defined in ART-CC as treatment with at least 3 drugs from 
2 different classes and in COHERE as the concomitant use of at least three antiretroviral drugs) for 
at least three years, 3) after start of cART had a period with suppressed VL of at least three years 
(all VL≤500 HIV-1 RNA copies/ml and never a time span of more than 7 months between VL 
measurements), 4) had a CD4 cell count ≤200 cells/µL at the start of the virally suppressed period 
(figure 1). Individuals enrolled in more than one cohort were identified and only one record per 
individual was included. A VL cut-off of ≤500 copies/ml was chosen in order to overcome the 
heterogeneity of the assay detection limits used during the study period. 
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Statistical Analysis 
Risk factors for failure to achieve a CD4 count >200 cells/µL after three years of viral suppression 
We used logistic regression to identify risk factors for not achieving CD4 count >200 cells/µL after 
three years of sustained viral suppression. We assessed the effect of CD4 count at the start of the 
suppressed period as a categorical variable (0-25, 26-50, 51-100, 101-150 and 151-200 cells/µL). In 
a sensitivity analysis, we fitted separate models for each of these CD4 strata. The following 
variables were included in all models: age at start of virally suppressed period (years; <30, 30-39, 
40-49, ≥50), probable route of infection/gender (men who have sex with men (MSM), male 
heterosexuals, female heterosexuals, injection drug use (IDU), other/unknown (the number of male 
and female IDUs and other/unknowns did not allow for further classification according to gender), 
pre-cART VL (last VL available within three months before start of cART or first VL within a 
month after start of cART if the former was not available; VL <100,000 copies/ml, ≥100,000 
copies/ml and missing), year of cART initiation (1996-1997, 1998-2000, 2001-), time from cART 
initiation to start of suppressed period (<12 months, ≥12 months), AIDS (no AIDS event, ≥1 AIDS 
event before start of the virally suppressed period). We tested for interactions between pairs of 
variables. 
Risk factors for mortality after 3 years of viral suppression 
Person-years at risk were calculated from the date of the first CD4 count within three months after 
three years of viral suppression to the earlier of time of death, loss to follow-up or end of 
observation. We estimated mortality rates and Kaplan Meier plots according to CD4 count at the 
end of the three year virally suppressed period (≤200, 201-350, 351-500 or >500 cells/µL) and used 
Cox regression to estimate hazard ratios (HR) for death according to these CD4 count groups. All 
analyses were adjusted for the covariates listed above (AIDS events in this analysis were up to the 
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end of the virally suppressed period) and stratified by cohort. We used Cox regression to compare 
individuals with CD4 counts ≤200 cells/µL and >200 cells/µL at the end of the suppressed period 
within strata defined by: age at start of virally suppressed period, route of infection/gender, AIDS 
status, and CD4 at start of suppressed period. In sensitivity analyses we (1) used a cut-off value of 
50 copies/ml to define viral suppression and (2) included only study subjects reporting sexual route 
of transmission and no positive test for hepatitis C virus (HCV) co-infection (HCV was defined as a 
positive test for HCV RNA or a positive test for HCV IgG antibody at any time during follow-up). 
Analysis of causes of death 
COHERE does not collect data on causes of death, so these analyses were restricted to individuals 
included in ART-CC. Online supplement 1 describes how the causes of death data in this study 
were assigned and categorized. Causes of death were further categorized as AIDS defining, non-
AIDS defining, unnatural (accident/violent/suicide/drug abuse) and unknown (12). Non-AIDS 
causes of death were further divided into hepatitis, cancers and other. As analyses of different 
causes of death can pose the problem of competing risks, we estimated both sub-distribution HRs 
(using the Fine and Gray approach) and standard (Cox) HRs (adjusted only for age and gender due 
to the small number of events) (13). Because these estimates did not differ appreciably, we report 
only the estimates from Cox models. SPSS statistical software, Version 15.0 (Norusis; SPSS Inc., 
Chicago, Illinois, USA) and R software, version 2.8.1, were used for data analysis. 
 
Results 
We identified 113,845 unique HIV-1 positive individuals from the COHERE and ART-CC cohorts, 
of whom 41,081 were treated with cART for <3 years, 50,495 did not have sustained viral 
suppression and 368 had no available CD4 measurement at the start of the suppressed period. Of 
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21,901 individuals who achieved sustained viral suppression for three years or more, 16,193 had 
CD4 count >200 cells/µL at start of the virally suppressed period and 158 had no available CD4 
measurement at the end of the suppressed period, leaving 5550 individuals (20,291 person years of 
observation, median follow-up time 3.4 years, IQR 1.6–5.3 years) eligible for analyses (figure 1). A 
histogram of the distribution of CD4 count at the start of the virally suppressed period is shown in 
online supplement 2. The majority of these (4715; 85.0%) achieved CD4 count >200 cells/µL after 
three years of viral suppression. Half (2904; 52.3%) were aged >40 years at the start of the 
suppressed period (table 1). 
Risk factors for failure to achieve CD4 count >200 cells/µL 
We found that risk of failure to achieve a CD4 count >200 cells/µL increased with increasing age 
and with decreasing CD4 count at start of the virally suppressed period (table 2). Compared with 
MSM, males with heterosexual route of infection, IDU, and those with other or unknown 
transmission group had greater risk of incomplete CD4 recovery. Risk was also greater in those 
whose last viral load before start of cART was <100,000 copies/ml, those who initiated cART after 
1998 and those who had 12 months or more from initiation of cART to start of the virally 
suppressed period. In models stratified on CD4 at start of the suppressed period, the impact of age 
and AIDS defining illness on incomplete CD4 recovery appeared similar across CD4 strata (online 
supplement table 1). Patients infected via IDU had consistently higher risk of incomplete CD4 
recovery than those infected via MSM. 
Time to death from any cause 
A total of 175 (3.2%) individuals died: 66 (7.9%) of those who did not attain CD4 count >200 
cells/µL and 109 (2.3%) of those who attained CD4 count >200 cells/µL. Table 3 shows that 
individuals who did not attain CD4 count >200 cells/µL after three years of sustained viral 
suppression had substantially increased mortality compared with those who achieved CD4 count 
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>200 cells/µL (adjusted HR (95% CI); 2.60 (1.86-3.81)). The cumulative probability of survival 
stratified by CD4 count are presented in figure 2. The estimated 5-year cumulative mortality 
(95%CI) was 11.8% (8.9%-15.2%) in patients with CD4 count <200 cells/µL at the end of the 
suppressed period, compared with 4.1% (3.1%-5.3%), 2.2% (1.4%-3.4%) and 2.2% (1.2%-3.7%) in 
patients with CD4 count 201-350, 351-500 and >500 cells/µL at the end of the suppressed period. 
Compared to individuals with CD4 count >500 cells/µL at the end of the suppressed period, 
adjusted HR (95%CI) in individuals with 351-500, 201-350 and ≤200 CD4 cells/µL were 0.62 
(0.32-1.19), 1.28 (0.74-2.23) and 2.62 (1.47-4.67), respectively. 
Mortality hazard ratios stratified on risk factors  
Table 3 shows that the impact on mortality of not achieving CD4 count >200 cells/µL was most 
pronounced in individuals whose CD4 count at the start of the suppressed period was 151-200 
cells/µL (those in whom the increase in CD4 since start of ART was lowest). However, estimated 
hazard ratios within CD4 strata were estimated imprecisely, and their confidence intervals 
overlapped. The impact of incomplete CD4 recovery appeared similar across strata defined by age, 
mode of transmission, viral load before start of cART, year of cART initiation, time from initiation 
of cART to start of the virally suppressed period and AIDS defining disease (table 3).  
Sensitivity analyses 
Of 2692 individuals who were eligible when a cut-off of 50 copies/ml for viral suppression was 
used, 2253 (83.7%) achieved CD4 count >200 cells/µL. Estimated effects of risk factors for not 
achieving a CD4 count >200 cells/µL were broadly similar to those in the main analyses, although 
there was less evidence of elevated risk among heterosexual males (adjusted odds ratio (95%CI); 
1.17 (0.88-1.55)) and females (0.64 (0.45-0.93)) (online supplement table 2). In this analysis a total 
of 33 (7.5%) and 41 (1.8%) individuals with and without incomplete CD4 recovery respectively 
died during follow-up, and the adjusted HR for not attaining (compared with attaining) CD4 count 
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>200 cells/µL was 3.96 (95% CI; 2.36 – 6.66). Exclusion of 1625 (29.3%) individuals who did not 
report sexual route of transmission nor had HCV co-infection left 3925 individuals with 87 deaths. 
The adjusted HR for not attaining (compared with attaining) CD4 count >200 cells/µL was 2.98 
(95% CI; 1.85 – 4.79). 
Time to death from specific causes 
Of 4135 individuals included in analyses of cause-specific mortality, 619 (15.0%) did not attain 
CD4 count >200 cells/µL after the suppressed period and 121 (2.9%) died. Most deaths were from 
non-AIDS defining causes, in both groups (table 4). Mortality due to AIDS-defining, non-AIDS 
defining and unnatural causes of death was increased substantially in individuals who did not attain 
CD4 count >200 cells/µL and was highest for hepatitis and non-AIDS defining cancers (adjusted 
HRs (95%CI); 6.76 (1.93–23.74) and 2.89 (1.44-5.28)). 
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Discussion 
Based on data combined from two large international HIV cohort collaborations, we found that 
among HIV positive individuals with three years of viral suppression on cART, those with 
incomplete CD4 recovery (CD4 count ≤200 cells/µL) had markedly higher mortality rates than 
those who achieved CD4 count >200 cells/µL. These higher rates were observed consistently across 
strata defined by age, gender, transmission group and prior AIDS-defining illness. Rates of both 
AIDS- and non-AIDS-defining causes of death were elevated. We identified older age, transmission 
via male heterosexual sex or IDU, lower CD4 count at start of the suppressed period and longer 
time from initiation of cART to start of the virally suppressed period as risk factors for incomplete 
CD4 cell recovery.  
Strengths and weaknesses. 
Since 15% of treated HIV positive individuals have CD4 count <200 cells/µl after long-term viral 
suppression, prognosis of such patients is a major concern. By combining data from two 
collaborations of HIV cohort studies, we assembled a sufficiently large dataset to permit us to 
examine both risk factors and prognosis for all-cause and cause-specific mortality among patients 
with incomplete CD4 recovery. The contributing cohort studies represent a wide variety of 
countries and settings, and our results are therefore likely to be generalizable to treated HIV positive 
people in Western Europe and North America. Not all contributing cohorts link their data with 
national death registries, which may lead to an underestimation of mortality rates. However 
estimates of relative mortality comparing different groups should not be biased, providing that non-
ascertained deaths are missing at random (MAR) (14). Serological tests for co-infection with HCV 
were not performed systematically in all cohorts, therefore some co-infected individuals may have 
been misclassified. However, findings were similar in a sensitivity analysis excluding both IDUs 
and HCV co-infected individuals, and the impact of misclassification of HCV sero-status may have 
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been limited because of its strong association with transmission via IDU, which was available from 
all cohorts. We did not have access to data on smoking, other comorbidity (for example diagnosis of 
non-AIDS cancers) or non-cART medications (for example cancer chemotherapy) and were 
therefore not able to adjust for such factors or assess whether they predict incomplete CD4 
recovery. 
Our definition of CD4 recovery (CD4 count >200 cells/µL after three years of viral suppression 
following cART initiation) differs from other definitions of recovery: for example NIH guidelines 
defined an adequate response as an increase in CD4 count in the range of 50 to 150 cells/µL per 
year (15). Our definition of CD4 recovery was based on two considerations. First, the increase in 
CD4 count over time since start of cART in virologically suppressed patients depends on baseline 
CD4 count (6). Second, the risk of mortality is strongly related to current CD4 count (16;17). 
Results in context with other literature 
Previous studies have identified age (8;18;19) and low baseline CD4 counts (4;18;20) as risk factors 
for incomplete CD4 cell recovery. However two of these (16;20) used designs that differed from 
ours in terms of inclusion criteria and length of the virally suppressed period. The effect of age 
observed in our study is consistent with its association with thymus size and activity and suggests 
that initiation of cART before immune-incompetence is especially important in older HIV 
individuals (21-23).  
Most studies that examined clinical endpoints according to achieved CD4 count in virally 
suppressed patients used short periods of viral suppression or did not have inclusion criteria relating 
to baseline CD4 count (9;17;24). These studies mainly estimated short term effects of changes in 
CD4 count, rather than elucidating the long term impact of sustained low CD4 cell counts in long-
term virally suppressed patients. Two previous studies examined implications of incomplete CD4 
16 
 
recovery among patients with sustained viral suppression and our findings are in accordance with 
their estimates. Loutfy et al. observed a 2.69-fold (95% CI 1.26-5.78) increase in mortality 
comparing 176 patients with CD4 count <200 cells/µl with 1545 patients with CD4 count >200 
cells/µl after 2 years of viral suppression (24). That study had both shorter duration of and less strict 
criteria for viral suppression as well as a much smaller and less generalizable sample. We 
previously reported the relative risk of death to be 3.4 (95% CI 1.4-8.0) in a small study comparing 
55 immunological non-responders with 236 responders in the Danish HIV Cohort Study, using a 
design almost identical to the present study (8). Data on causes of death were not available in either 
of these two studies. Although we observed increased mortality in all subgroups of individuals with 
poor CD4 recovery, the relative risk of death was greatest among individuals with baseline CD4 
count between 151 and 200 cells/µL. These individuals are characterized by the lowest increase (or 
even a decrease) in CD4 counts during the three year period of virological suppression, a 
phenomenon which may be related to non-HIV comorbidity such as cancer. 
 Consistent with our results, previous studies have found incomplete CD4 recovery to be associated 
with an increased risk of non-AIDS cancer (25-27). It is still a matter of debate whether low CD4 
counts lead to non-AIDS defining cancers or whether common risk factors lead to low CD4 count 
and non-AIDS defining cancers. Higher rates of non-AIDS mortality among individuals with 
incomplete CD4 recovery may be related to chronic immune activation in virally suppressed 
individuals (28;29). 
Implications and conclusions 
Our data underline the importance of early diagnosis of HIV and treatment with cART before 
patients have a low CD4 count. Although we have identified risk factors for poor CD4 recovery, no 
interventions to increase CD4 count in virally suppressed patients have been demonstrated to have 
beneficial effects on clinical endpoints and mortality. Previous studies have not consistently 
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demonstrated differences between antiretroviral drug classes in effects on CD4 increases, and 
attempts to increase CD4 count with Il-2 were futile in terms of clinical benefit (30-32). Virally 
suppressed patients with low CD4 counts should be monitored closely for diseases not 
conventionally considered HIV-related, especially non-AIDS defining cancers and liver diseases. 
Our study demonstrated an increased risk of non-AIDS causes of death in immunological non-
responders: further research is needed to elucidate the mechanisms that lead to persistently low CD4 
counts despite viral suppression.
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Table 1. Clinical and demographic characteristics of 5550 eligible HIV individuals, according to 
CD4 count at end of the virally suppressed period. ART-CC and COHERE HIV multicohort 
collaboration 2012.  
 CD4 count at end of virally suppressed 
period 
Characteristic ≤200 cells/µL  >200 cells/µL  
Number (person-years of observation) 835 (2936) 4715 (17355) 
   
Deaths (mortality rate per 100 PYR) 66   (2.2) 109   (0.6) 
   
Median time from start of cART to start of the 
suppressed period, months (IQR) 
2.8 (1.3-12.1) 2.5   (1.2-5.5) 
Age at start of the suppressed period (years)   
      <30 (%) 45    (5.4) 512   (10.9) 
     30-39 (%) 233 (27.9) 1956 (41.5) 
     40-49 (%) 275 (32.9) 1440 (30.5 
     >50 (%)  282 (33.8) 907   (17.1) 
   
Route of infection/Gender   
     MSM (%) 227 (27.2) 1695 (35.9) 
     Male heterosexuals (%) 216 (25.9) 995   (21.1) 
     Female heterosexuals (%) 101 (12.1) 933   (19.8) 
     IDU (%) 128 (15.3) 489   (10.4) 
     Other/unknown (%) 163 (18.6) 603   (12.8) 
   
CD4 count at start of the suppressed period   
     ≤25 (%) 75    (9.0) 223   (4.7) 
     26-50 (%) 108 (12.9) 370   (7.8) 
     51 - 100 (%) 268 (32.1) 970   (20.6) 
     101 -150 (%) 231 (27.7) 1377 (29.2) 
     151 – 200 (%) 153 (18.3) 1775 (37.6) 
   
Last viral load before start of cART (copies/ml)   
     < 100,000 (%)  391 (46.8) 2129 (38.4) 
     ≥ 100,000 (%) 424 (50.8) 2470 (44.5) 
     VL missing (%)   20 (2.4)   116 (2.5) 
   
Year of start of cART   
1996-1997 69    (8.3) 442   (9.4) 
1998 - 2000 336 () 1686 (35.8) 
2001 - 430 (51.5) 2587 (54.9) 
   
Time from cART initiation to start of suppressed period  
<12 months 626 (75.0) 3952 (83.8) 
≥12 months 209 (25.0) 763     (16.2) 
   
One or more AIDS events before start of 
suppressed period (%) 
  
     No AIDS 425 (51.9) 2580 (54.7) 
     AIDS 410 (49.1) 2135 (45.3) 
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PYR = person-years at risk; cART = combination antiretroviral therapy; IQR = inter quartile range; 
MSM = men who have sex with men; IDU = injection drug use; VL = viral load; AIDS = acquired 
immune deficiency syndrome.  
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Table 2. Factors associated with failure to achieve CD4 count > 200 cells/µL after three years of 
viral suppression on cART. ART-CC and COHERE HIV multicohort collaboration 2012.  
 Unadjusted odds 
ratio (95%CI) 
Adjusted odds 
ratio (95%CI) 
Age at start of the suppressed period (years)   
 <30 1      (reference) 1      (reference) 
30-39 1.36 (0.97-1.89) 1.31 (0.93-1.85) 
40-49 2.17 (1.56-3.03) 2.04 (1.45-2.88) 
≥50 3.98 (2.85-5.55) 4.01 (2.84-5.68) 
   
Route of infection/ Gender   
MSM 1      (reference) 1 (reference) 
Male hetero  1.62 (1.32-1.98) 1.50 (1.21-1.85) 
Female hetero  0.81 (0.63-1.04) 0.89 (0.68-1.15) 
IDU  1.96 (1.54-2.48) 2.03 (1.57-2.61) 
Other/unknown  2.02 (1.62-2.52) 1.72 (1.37-2.17) 
   
CD4 count (cells/µL) at start of suppressed period  
≤25 3.90 (2.86-5.32) 5.21 (3.75-7.23) 
26-50 3.39 (2.58-4.44) 4.46 (3.35-5.95) 
51-100 3.21 (2.59-3.97) 3.73 (2.99-4.68) 
101-150 1.95 (1.57-2.42) 2.08 (1.67-2.60) 
151-200 1      (reference) 1     (reference) 
   
Last viral load before start of cART **   
< 100,000 copies/ml 1.07 (0.92-1.24) 1.13 (0.97-1.33) 
≥100,000 copies/ml 1      (reference) 1     (reference) 
   
Year of start of cART   
1996-1997 1      (reference) 1      (reference) 
1998 - 2000 1.28 (0.97-1,69) 1.44 (1.07-1.93) 
2001 - 1.07 (0.81-1.40) 1.37 (1.02-1.84) 
   
Time from cART initiation to start of suppressed period  
<12 months 1      (reference) 1      (reference) 
≥12 months 1.73 (1.45-2.06) 2.05 (1.68-2.50) 
   
One or more AIDS events before start of 
suppressed period 
  
       No AIDS 1.17 (1.01-1.35) 0.89 (0.76-1.04) 
       AIDS 1      (reference) 1      (reference) 
MSM = men who have sex with men; IDU = injection drug use; cART = combination antiretroviral 
therapy; AIDS = acquired immune deficiency syndrome. 
* Adjusted for all other covariates listed in the table.  
** 136 individuals had no baseline VL and were included in the analysis as missing VL. 
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Table 3. Mortality hazard ratios comparing individuals with CD4 count ≤200 and >200 cells/µL at the end of suppressed period, overall 
and stratified on CD4 count at start of suppressed period, age, mode of transmission and AIDS defining events. ART-CC and COHERE 
HIV multicohort collaboration 2012.  
Strata Deaths (N) 
 
Person-time of 
observation (years)  
Crude HR 
(95%CI) 
Adjusted* HR 
(95%CI) 
 ≤200 
cells/µL 
>200 
cells/µL 
≤200 
cells/µL  
>200 
cells/µL 
  
        
All individuals  66 109 2937 17346 3.35 (2.46-4.57) 2.60 (1.86-3.61) 
Strata: Age (years)   
     <30  1 2 154 1826 NA NA 
     30-39  8 25 863 7457 3.00 (1.33-6.76) 3.01 (1.26-7.16) 
     40-49  19 40 937 5174 2.50 (1.44-4.34) 2.04 (1.12-3.70) 
     ≥50  38 42 983 2889 2.51 (1.61-3.93) 3.18 (1.96-5.14) 
       
Strata: Route of transmission/ Gender   
     MSM 13 30 84 6694 3.58 (1.85-6.93) 2.62 (1.28-5.34) 
     Male heterosexual  14 25 729 3516 2.86 (1.47-5.57) 2.41 (1.19-4.86) 
     Female heterosexual  7 7 298 2975 8.21 (2.80-24.05) NA 
     IDU  12 27 461 1810 1.60 (0.78-3.27) 1.43 (0.65-3.17) 
     Other/unknown 20 20 605 2350 3.13 (1.68-5.83) 2.53 (1.26-5.07) 
       
Strata: CD4 count at start of suppressed period   
     ≤25 cells/µL 6 2 317 904 NA NA 
     26-50 cells/µL  6 5 452 1386 2.92 (0.86-9.93) 2.76 (0.66-11.46) 
     51-100 cells/µL  17 26 973 3731 2.56 (1.35-4.85) 1.43 (0.71-2.88) 
     101-150 cells/µL 22 40 735 5022 3.40 (2.00-5.75) 2.62 (1.49-4.60) 
     151-200 cells/µL 15 36 459 6303 5.57 (3.01-10.32) 3.82 (1.95-7.45) 
       
Strata: Last viral load before start of cART   
     Viral load <100,000 copies/ml  30 51 1365 7520 2.98 (1.88-4.72) 2.23 (1.34-3.72) 
     Viral load ≥100,000 copies/ml  33 58 1517 9504 3.19 (2.06-4.94) 2.61 (1.63-4.18) 
       
29 
 
Strata: Year of cART initiation   
     1996-1997 8 22 394 2750 2.87 (1.24-6.64) 2.25 (0.87-5.84) 
     1998-2000  40 56 1535 8453 3.65 (2.42-5.51) 2.74 (1.74-4.30) 
     2001- 18 31 1008 6143 3.39 (1.87-6.14) 3.03 (1.62-5.65) 
       
Strata: Time from cART initiation to start of 
suppressed period 
  
     <12 months 18 18 573 2336 3.04 (2.13-4.33) 2.51 (1.23-5.14) 
     ≥12 months 48 91 2363 15010 3.96 (2.03-7.70) 2.53 (1.72-3.70) 
       
Strata: One or more AIDS events by end of 
suppressed period 
  
     No AIDS       28 48 13507 8584 3.51 (2.18-5.64) 2.49 (1.47-4.20) 
     AIDS  38 61 1587 8762 3.05 (2.02-4.61) 2.47 (1.59-3.83) 
       
HR = hazard ratio; MSM = men who have sex with men; IDU = injection drug use; cART = combination antiretroviral therapy; AIDS = 
acquired immune deficiency syndrome. 
* Adjusted for all other covariates listed in the table. Stratification factor removed from list of adjustments.  
NA: numbers in these strata were too small for an analysis to be performed 
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Table 4. Cause-specific hazard ratios comparing HIV individuals (ART-CC only) with CD4 count 
≤200 vs. >200 cells/µL at end of suppressed period. ART-CC and COHERE HIV multicohort 
collaboration 2012.  
 
Causes of death 
 
Number (%) of deaths 
according to CD4 count at 
end of suppressed period 
HR  
(95% confidence interval) 
 
≤200 cells/µL  
 
>200 
cells/µL  
 
Unadjusted  
 
Adjusted*     
All  41 (100) 80 (100) 3.05 (2.10- 4.44) 2.52 (1.71-3.70) 
     
AIDS defining causes 
of death 
4 (9.8) 7 (8.8) 3.39 (0.99-11.57) 2.75 (0.78-9.69) 
     
Non-AIDS defining 
causes of death 
26 (63.4) 49 (61.3) 3.14 (1.95-5.06) 2.61 (1.61-4.23) 
Hepatitis 5 5 5.95 (1.72-20.56) 6.76 (1.93-
23.74) 
Non-AIDS cancer 14 23 3.50 (1.73-6.95) 2.89 (1.44-5.28) 
Other causes of 
death** 
6 21 1.69 (0.68-4.18) 1.24 (0.50-3.12) 
     
Unnatural causes of 
death 
3 (7.3) 8 (10.0) 2.27 (0.60-8.57) 2.07 (0.54-7.97) 
     
Unknown causes of 
death 
8 (19.5) 16 (19.5) 3.00 (1.28-7.01) 2.34 (0.98-5.59) 
HR = hazard ratio; AIDS = acquired immune deficiency syndrome. 
*Adjusted for gender and age (<=50 years vs. >50 years) 
**Other causes of death for patients with CD4 count ≤200 cells/µL were; 2 related to infection, 2 
related to cardiovascular disease, 2 related to digestive system disease. Other causes of death for 
patients with CD4 count >200 cells/µL  were related to infection (5) lung diseases (2), 
cardiovascular diseases (9), digestive system diseases (2), central nervous system diseases (2) and 
renal diseases (1). 
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Figure 1. Flowchart and study timeline. ART-CC and COHERE HIV multicohort 
collaboration 2012.  
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Figure 2. Cumulative probability of survival stratified by CD4 count at the end of the virally 
suppressed period: 1) CD4 ≤200 cells/µL (full line), 2) 200 <CD4 ≤ 350 cells/µL (broken line), 3) 
350 < CD4 ≤500 cells/µL (dotted line) and 4) CD4>500 cells/µL (broken and dotted line).  ART-
CC and COHERE HIV multicohort collaboration 2012.  
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CD4>500             ─∙─∙ 
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